Optinose Inc Quick Ratio (OPTN) starting from the first quarter 2025 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Optinose Inc   (NASDAQ: OPTN)

Optinose Inc 's Quick Ratio

OPTN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2025, Quick Ratio fell to 0.42 below Optinose Inc average.

Within Major Pharmaceutical Preparations industry 475 other companies have achieved higher Quick Ratio than Optinose Inc in first quarter 2025. While Quick Ratio total ranking in the first quarter 2025 has deteriorated compared to the prior quarter from 2334 to 3082.

Explain Quick Ratio?
How much Cash & cash equivalents OPTN´s has?
What are OPTN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OPTN Quick Ratio (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1
Y / Y Current Liabilities Change 435.11 % -7.77 % -0.95 % -80.1 % -80.33 %
Y / Y Cash & cash equivalent Change 41.22 % 14.66 % 23.42 % 28.11 % -38.47 %
Quick Ratio MRQ 0.42 0.52 0.51 2.79 1.58
OPTN's Total Ranking # 3082 # 2334 # 2124 # 543 # 1255
Seq. Current Liabilities Change 7.49 % 0.24 % 396.73 % -0.02 % -81.47 %
Seq. Cash & cash equivalent Change -13.67 % 2.41 % -9.7 % 76.9 % -29.91 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 476
Healthcare Sector # 870
Overall Market # 3082


Quick Ratio Statistics
High Average Low
15.89 3.73 0.34
(Dec 31 2017)   (Sep 30 2022)




Financial Statements
Optinose Inc 's Current Liabilities $ 175 Millions Visit OPTN's Balance sheet
Optinose Inc 's Cash & cash equivalent $ 73 Millions Visit OPTN's Balance sheet
Source of OPTN's Sales Visit OPTN's Sales by Geography


Cumulative Optinose Inc 's Quick Ratio

OPTN's Quick Ratio for the trailling 12 Months

OPTN Quick Ratio

 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -0.85 % -41.79 % -39.94 % -40.93 % -6.98 %
Y / Y Cash & cash equivalent TTM Growth 25.73 % 4.81 % -5.42 % -8.7 % -17.02 %
Quick Ratio TTM 0.62 0.79 0.74 0.7 0.49
Total Ranking TTM # 2546 # 3456 # 3414 # 2298 # 2297
Seq. Current Liabilities TTM Growth 36.43 % -3.39 % -0.38 % -24.48 % -19.91 %
Seq. Cash & cash equivalent TTM Growth 6.87 % 3.61 % 5.52 % 7.61 % -10.92 %

Quick ratio ranking by company, industry and sector >> Back to OPTN Financial Strength Comparisons >> Go to Compare OPTN Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q1 2025 to $175.01 millions, cumulative Quick Ratio decreased to 0.62 below the Optinose Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 354 other companies have achieved higher Quick Ratio than Optinose Inc . While Quick Ratio overall ranking has improved so far to 2546, from total ranking during the twelve months ending fourth quarter 2024 at 3456.

Explain Quick Ratio?
How much Cash & cash equivalents OPTN´s has?
What are OPTN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 355
Healthcare Sector # 703
Within the Market # 2546


trailing twelve months Quick Ratio Statistics
High Average Low
6 2.2 0.44
(Sep 30 2019)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Decoy Therapeutics Inc   1.14 $ 1.798  Millions$ 1.583  Millions
Avadel Pharmaceuticals Plc  1.12 $ 56.387  Millions$ 50.227  Millions
Moleculin Biotech Inc   1.12 $ 7.716  Millions$ 6.896  Millions
Nervgen Pharma Corp   1.12 $ 16.905  Millions$ 15.115  Millions
Durect Corp  1.08 $ 8.260  Millions$ 7.673  Millions
Puma Biotechnology Inc   1.08 $ 93.167  Millions$ 86.663  Millions
Abbott Laboratories  1.07 $ 6,844.000  Millions$ 6,372.000  Millions
Fibrobiologics Inc   1.06 $ 8.667  Millions$ 8.211  Millions
Kamada Ltd   1.04 $ 76.250  Millions$ 73.214  Millions
Supernus Pharmaceuticals inc   1.04 $ 115.848  Millions$ 111.639  Millions
Johnson and Johnson  1.02 $ 38,781.000  Millions$ 38,123.000  Millions
Rockwell Medical inc   1.02 $ 11.391  Millions$ 11.205  Millions
Evotec Se  1.01 $ 360.490  Millions$ 356.680  Millions
Verrica Pharmaceuticals Inc   1.01 $ 29.595  Millions$ 29.396  Millions
Sarepta Therapeutics Inc   0.93 $ 522.762  Millions$ 560.729  Millions
Royalty Pharma Plc  0.93 $ 1,099.820  Millions$ 1,182.852  Millions
Ibio inc   0.92 $ 4.985  Millions$ 5.397  Millions
Prestige Consumer Healthcare Inc   0.92 $ 97.884  Millions$ 106.623  Millions
Nanobiotix S a   0.92 $ 59.080  Millions$ 64.408  Millions
Oragenics Inc   0.92 $ 3.421  Millions$ 3.731  Millions
Clene Inc   0.91 $ 9.832  Millions$ 10.764  Millions
Incannex Healthcare Inc  0.91 $ 6.711  Millions$ 7.368  Millions
Bausch Health Companies Inc   0.86 $ 1,134.000  Millions$ 1,315.000  Millions
Nurix Therapeutics Inc   0.84 $ 75.916  Millions$ 89.988  Millions
Os Therapies Incorporated  0.84 $ 2.971  Millions$ 3.536  Millions
Rani Therapeutics Holdings Inc   0.79 $ 15.853  Millions$ 20.130  Millions
Karyopharm Therapeutics Inc   0.77 $ 69.941  Millions$ 90.370  Millions
Keenova Therapeutics Plc  0.76 $ 348.200  Millions$ 457.700  Millions
Ani Pharmaceuticals Inc  0.74 $ 149.802  Millions$ 201.815  Millions
Carisma Therapeutics Inc   0.74 $ 7.740  Millions$ 10.447  Millions

Date modified: 2026-08-29T17:41:32+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.